Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2026, Gilead Sciences (GILD) reported revenue of $6.96 billion, up 4.4% over the same period last year. EPS came in at $2.03, compared to $1.81 in the year-ago quarter.The reported revenue represents a surprise of +0.95% over the Zacks Consensus Estimate of $6.89 billion. With the consensus EPS estimate being $1.89, the EPS surprise was +7.68%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Product Sales- Oncology- Trodelvy- U.S.: $253 million compared to the $222.88 million average estimate based on three analysts. The reported number represents a change of +39.8% year over year.Product Sales- Liver Disease- Other Liver Disease- U.S.: $15 million compared to the $157.8 million average estimate based on three analysts. The reported number represents a change of -77.9% year over year.Product Sales- Liver Disease- Vemlidy- U.S.: $91 million compared to the $104.18 million average estimate based on three analysts. The reported number represents a change of -9% year over year.Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.: $141 million versus the three-analyst average estimate of $121.36 million. The reported number represents a year-over-year change of -15.1%.Total product sales- Total: $6.95 billion compared to the $6.83 billion average estimate based on five analysts. The reported number represents a change of +5% year over year.Revenues- Royalty contract and other revenues: $14 million compared to the $42.52 million average estimate based on five analysts. The reported number represents a change of -74.1% year over year.Product Sales- Liver Disease- Vemlidy- Total: $237 million versus the four-analyst average estimate of $221.37 million. The reported number represents a year-over-year change of -6%.Product Sales- Oncology- Cell Therapy- Yescarta- Total: $332 million compared to the $364.23 million average estimate based on four analysts. The reported number represents a change of -14% year over year.Product Sales- HIV- Biktarvy- Total: $3.36 billion versus $3.3 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.7% change.Product Sales- HIV- Symtuza-Revenue share- Total: $138 million compared to the $112.33 million average estimate based on four analysts. The reported number represents a change of +21.1% year over year.Product Sales- Veklury- Total: $144 million compared to the $182.98 million average estimate based on four analysts. The reported number represents a change of -52.3% year over year.Product Sales- HIV- Odefsey- Total: $221 million compared to the $240.94 million average estimate based on four analysts. The reported number represents a change of -21.4% year over year.View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned -3.7% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks